ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer

Use of first-line (1L) OPDIVO^® (nivolumab) in combination with low-dose YERVOY^® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%

The Lynx Group: 2021 Ask The Expert MDietrich.pdf

Please Click the Issue to Download

Introduction

This resource provides insights and guidance by a thought leader into frequently asked questions on the open-label, phase 3, Checkmate 227 study evaluating the use of 1L nivolumab in combination with low-dose ipilimumab in patients with metastatic NSCLC and PD-L1 ≥1%

Download to Continue Reading

Home
Issues
Special Issues
- Supplements
  - ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
    - Part 1
    - Part 2
- Guide to New FDA Approvals
Categories
Conference Correspondent
- ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Quick Quiz
CE
About

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

First Name *

Last Name *

Email Address *

Email Address (Verify) *

TOP E-Newsletters and Communications

JHOP E-Newsletters and Communications

ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer

Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%

Introduction

Use of first-line (1L) OPDIVO^® (nivolumab) in combination with low-dose YERVOY^® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%